Cholangiocarcinoma

0 curated biomarkers

← Back to browse

FDA-approved treatments

No biomarkers are curated under Cholangiocarcinoma yet.

Prevalence

No biomarkers are curated under Cholangiocarcinoma yet.

Tests / detection method

No biomarkers are curated under Cholangiocarcinoma yet.

Therapeutic pipeline

No biomarkers are curated under Cholangiocarcinoma yet.

PubMed Central · Aug 28, 2026
Cholangioblastic variant of intrahepatic cholangiocarcinoma in a young adult with situs inversus totalis.
Read at PubMed Central
PubMed Central · Aug 26, 2026
Early recurrence prediction after curative-intent surgery of intrahepatic cholangiocarcinoma using a novel weighted tumor burden score.
Read at PubMed Central
PubMed Central · Aug 20, 2026
Tertiary lymphoid structure topotypes in intrahepatic cholangiocarcinoma: spatial immunity, checkpoint-response associations, and therapeutic reprogramming.
Read at PubMed Central
PubMed Central · Aug 20, 2026
From the invasive front to organotropic pre-metastatic niches: spatial immune regulatory networks governing cholangiocarcinoma dissemination and metastasis-intercepting immunotherapy.
Read at PubMed Central
PubMed Central · Aug 18, 2026
Effect of preoperative body composition on long-term outcomes in patients undergoing distal cholangiocarcinoma resection.
Read at PubMed Central
PubMed Central · Aug 11, 2026
Margin-enriched CD4(+) central-memory T cells affect macrophages via ANXA1-FPR1 signaling axis to promote tumor progression in intrahepatic cholangiocarcinoma.
Read at PubMed Central
PubMed Central · Jul 2, 2026
Extracellular matrix reprogramming by the YAP/TAZ/TGF-β2 axis drives immune exclusion in cholangiocarcinoma models.
Read at PubMed Central
PubMed Central · Jun 25, 2026
Perineural invasion in intrahepatic cholangiocarcinoma: Meta-analysis of prevalence, association with tumor features, and impact on survival.
Read at PubMed Central
PubMed Central · Jun 23, 2026
Dose-Response and survival analysis after transarterial radioembolization for intrahepatic cholangiocarcinoma: A multicenter multicompartment dosimetry study.
Read at PubMed Central
PubMed Central · Jun 14, 2026
Tumor Burden Modifies the Prognostic Impact of Adequate Lymph Node Dissection in Patients Undergoing Curative-Intent Resection for Intrahepatic Cholangiocarcinoma.
Read at PubMed Central

Cholangiocarcinoma

FDA-approved treatments

Prevalence

Tests / detection method

Therapeutic pipeline

Recent news for Cholangiocarcinoma

Cholangioblastic variant of intrahepatic cholangiocarcinoma in a young adult with situs inversus totalis.

Early recurrence prediction after curative-intent surgery of intrahepatic cholangiocarcinoma using a novel weighted tumor burden score.

Tertiary lymphoid structure topotypes in intrahepatic cholangiocarcinoma: spatial immunity, checkpoint-response associations, and therapeutic reprogramming.

From the invasive front to organotropic pre-metastatic niches: spatial immune regulatory networks governing cholangiocarcinoma dissemination and metastasis-intercepting immunotherapy.

Effect of preoperative body composition on long-term outcomes in patients undergoing distal cholangiocarcinoma resection.

Margin-enriched CD4(+) central-memory T cells affect macrophages via ANXA1-FPR1 signaling axis to promote tumor progression in intrahepatic cholangiocarcinoma.

Extracellular matrix reprogramming by the YAP/TAZ/TGF-β2 axis drives immune exclusion in cholangiocarcinoma models.

Perineural invasion in intrahepatic cholangiocarcinoma: Meta-analysis of prevalence, association with tumor features, and impact on survival.

Dose-Response and survival analysis after transarterial radioembolization for intrahepatic cholangiocarcinoma: A multicenter multicompartment dosimetry study.

Tumor Burden Modifies the Prognostic Impact of Adequate Lymph Node Dissection in Patients Undergoing Curative-Intent Resection for Intrahepatic Cholangiocarcinoma.